Table 1.
Summary of economic features of the studies
| Feature | N | % |
|---|---|---|
| Type of economic evaluation | ||
| CEA | 8 | 42 |
| CUA | 11 | 58 |
| CMA | 0 | 0 |
| CBA | 0 | 0 |
| Study design | ||
| Randomised clinical trial (RCT) | 0 | 0 |
| Observational | 4 | 21 |
| Modelling | 15 | 79 |
| Perspective evaluated | ||
| Government/public sector | 4 | 21 |
| Provider | 8 | 42 |
| Program provider | 2 | 11 |
| Not specified | 5 | 26 |
| Time horizon | ||
| ≤ 1 year | 4 | 21 |
| 1–10 years | 4 | 21 |
| Over 10 years/lifetime | 5 | 26 |
| Not specified | 6 | 32 |
| Type of outcome | ||
| QALY/DALY | 11 | 58 |
| Infection averted | 12 | 63 |
| Infections cured | 3 | 16 |
| Level of care and intervention type | ||
| Behavior change | 1 | 5 |
| Biomedical interventions | 4 | 21 |
| Structural interventions | 1 | 5 |
| Mixed | 13 | 68 |
| Type of data used | ||
| Primary data | 2 | 11 |
| Secondary data | 15 | 79 |
| Mixed | 2 | 11 |
| Type of sensitivity analysis | ||
| One-way/univariate | 12 | 63 |
| Multi-way/multivariate | 8 | 42 |
| Probabilistic analysis | 6 | 32 |
| Not performed/specified | 2 | 11 |
CUA cost-utility analysis, CEA cost-effectiveness analysis, CMA cost-minimisation analysis, CBA cost-benefit analysis, QALY quality-adjusted life year, DALY disability-adjusted life year